Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Laternser

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Chimia|March 2, 2018
TEDD Annual Meeting with 3D Bioprinting WorkshopMichael Raghunath, Markus Rimann, Katarzyna S Kopanska, et al.
Chimia|October 29, 2015
3D Bioprinted Muscle and Tendon Tissues for Drug DevelopmentMarkus Rimann, Sandra Laternser, Hansjörg Keller, et al.
Chimia|October 7, 2017
3D Bioprinted Muscle and Tendon Tissues for Drug DevelopmentMarkus Rimann, Sandra Laternser, Hansjörg Keller, et al.
SLAS Technology|June 14, 2018
A Novel Microplate 3D Bioprinting Platform for the Engineering of Muscle and Tendon TissuesSandra Laternser, Hansjoerg Keller, Olivier Leupin, et al.
Journal of Biotechnology|September 20, 2014
An in vitro osteosarcoma 3D microtissue model for drug developmentMarkus Rimann, Sandra Laternser, Ana Gvozdenovic, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2022
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experienceTimothy Mueller, Sandra Laternser, Ana S Guerreiro Stücklin, et al.
Microsystems & Nanoengineering|October 10, 2025
A microfluidic platform for the co-culturing of microtissues with continuously recirculating suspension cellsChristian Lohasz, Tamara Häfeli, Dzhansu Hasanova, et al.
NPJ Precision Oncology|July 2, 2025
Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma modelsBavani Subramaniam, Debasish Roy, Ayda Woldegerima, et al.
Neuro-Oncology|May 24, 2026
Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapyMasahiro Okada, Bavani Subramaniam, Baobao Geng, et al.
Neuro-Oncology|February 14, 2022
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomasJustyna M Przystal, Chiara Cianciolo Cosentino, Sridevi Yadavilli, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Chimia|March 2, 2018
TEDD Annual Meeting with 3D Bioprinting WorkshopMichael Raghunath, Markus Rimann, Katarzyna S Kopanska, et al.
Chimia|October 29, 2015
3D Bioprinted Muscle and Tendon Tissues for Drug DevelopmentMarkus Rimann, Sandra Laternser, Hansjörg Keller, et al.
Chimia|October 7, 2017
3D Bioprinted Muscle and Tendon Tissues for Drug DevelopmentMarkus Rimann, Sandra Laternser, Hansjörg Keller, et al.
SLAS Technology|June 14, 2018
A Novel Microplate 3D Bioprinting Platform for the Engineering of Muscle and Tendon TissuesSandra Laternser, Hansjoerg Keller, Olivier Leupin, et al.
Journal of Biotechnology|September 20, 2014
An in vitro osteosarcoma 3D microtissue model for drug developmentMarkus Rimann, Sandra Laternser, Ana Gvozdenovic, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2022
Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experienceTimothy Mueller, Sandra Laternser, Ana S Guerreiro Stücklin, et al.
Microsystems & Nanoengineering|October 10, 2025
A microfluidic platform for the co-culturing of microtissues with continuously recirculating suspension cellsChristian Lohasz, Tamara Häfeli, Dzhansu Hasanova, et al.
NPJ Precision Oncology|July 2, 2025
Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma modelsBavani Subramaniam, Debasish Roy, Ayda Woldegerima, et al.
Neuro-Oncology|May 24, 2026
Single-nucleus profiling of postmortem diffuse midline gliomas identifies mitochondrial biogenesis as a resistance mechanism to imipridone therapyMasahiro Okada, Bavani Subramaniam, Baobao Geng, et al.
Neuro-Oncology|February 14, 2022
Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomasJustyna M Przystal, Chiara Cianciolo Cosentino, Sridevi Yadavilli, et al.
Pageof 2